STOCK TITAN

Veracyte (VCYT) Chief Dev and Tech Officer files initial Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

VERACYTE, INC. filed an initial insider ownership report for Kevin Richard Haas, who serves as Chief Development and Technology Officer. This Form 3 establishes his status as a reporting officer under SEC rules. The filing does not list any buy, sell, or other share transactions, focusing instead on his reporting obligation as a company insider.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Haas Kevin Richard

(Last)(First)(Middle)
C/O VERACYTE, INC.
6000 SHORELINE COURT, SUITE 300

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/24/2026
3. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Dev and Tech Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24.1 - Power of Attorney
No securities are beneficially owned.
/s/ Jonathan Wygant, as attorney-in-fact03/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Veracyte (VCYT) Form 3 filing for Kevin Richard Haas show?

The Form 3 shows that Kevin Richard Haas is a reporting insider at Veracyte as Chief Development and Technology Officer. It is an initial statement of beneficial ownership and does not report any share purchases or sales.

Did Kevin Richard Haas buy or sell Veracyte (VCYT) shares in this Form 3?

No transactions are reported in this Form 3. The transaction summary lists zero buys, zero sells, and zero derivative exercises, indicating the filing serves only to establish insider status and reporting obligations.

What insider role does Kevin Richard Haas hold at Veracyte (VCYT)?

Kevin Richard Haas is identified as an officer of Veracyte with the title Chief Development and Technology Officer. This role makes him subject to SEC insider reporting rules, which require filings such as Form 3, 4, and 5.

Does the Veracyte (VCYT) Form 3 include derivative securities for Kevin Richard Haas?

The filing’s derivative summary is empty, and derivativeTransactionCount is zero. This indicates that, in this specific Form 3, no options, warrants, or other derivative positions are reported for Kevin Richard Haas.

What is the overall transaction direction in the Veracyte (VCYT) Form 3 for Kevin Richard Haas?

The transaction summary shows netBuySellDirection as neutral, with all buy, sell, and exercise counts at zero. This confirms the Form 3 is purely an initial ownership statement without any reported trading activity.
Veracyte

NASDAQ:VCYT

View VCYT Stock Overview

VCYT Rankings

VCYT Latest News

VCYT Latest SEC Filings

VCYT Stock Data

2.61B
78.61M
Diagnostics & Research
Services-medical Laboratories
Link
United States
SOUTH SAN FRANCISCO